Prevalence of obesity and associated complications in China: A cross-sectional, real-world study in 15.8 million adults

IF 5.4 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes, Obesity & Metabolism Pub Date : 2023-08-17 DOI:10.1111/dom.15238

Kang Chen MD, Zewei Shen MMed, Weijun Gu MD, Zhaohui Lyu MD, Xuan Qi MD, Yiming Mu MD, Yi Ning MD, for the Meinian Investigator Group

{"title":"Prevalence of obesity and associated complications in China: A cross-sectional, real-world study in 15.8 million adults","authors":"Kang Chen MD, Zewei Shen MMed, Weijun Gu MD, Zhaohui Lyu MD, Xuan Qi MD, Yiming Mu MD, Yi Ning MD, for the Meinian Investigator Group","doi":"10.1111/dom.15238","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>To evaluate the prevalence of overweight/obesity and associated complications from a large, cross-sectional, nationwide database in China.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>Data were obtained from 519 Meinian health check-up centres across 243 cities. Eligible participants were aged ≥18 years, with a routine check-up in 2019 (N = 21 771 683) and complete height, weight, sex and region data. The unadjusted prevalence rates of overweight/obesity were calculated by age, sex and region. In addition, the nationwide prevalence rates of overweight and obesity were standardized according to the 2010 China census by age group and sex. The prevalence of obesity-related complications by body mass index (BMI) groups was calculated using logistic regression.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>There were 15 770 094 eligible participants (median age 40 years; mean BMI 24.1 kg/m<sup>2</sup>; 52.8% male). By Chinese BMI classification, 34.8% were overweight and 14.1% were obese. Overweight and obesity were more prevalent in male than female participants (standardized: overweight 40.2% vs. 27.4%; obesity 17.6% vs. 9.6%, respectively). The prevalence of assessed complications was higher in participants with overweight/obesity versus those with normal BMI (<i>P</i> < 0.001 for trends). The most prevalent complications in participants with overweight/obesity were fatty liver disease, prediabetes, dyslipidaemia and hypertension. The number of complications increased with higher BMI.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Overweight/obesity and related complications are highly prevalent in this population. These data may better inform management and prevention public health strategies in China.</p>\n </section>\n </div>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":"25 11","pages":"3390-3399"},"PeriodicalIF":5.4000,"publicationDate":"2023-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dom.15238","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/dom.15238","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 2

Abstract

Aim

To evaluate the prevalence of overweight/obesity and associated complications from a large, cross-sectional, nationwide database in China.

Materials and Methods

Data were obtained from 519 Meinian health check-up centres across 243 cities. Eligible participants were aged ≥18 years, with a routine check-up in 2019 (N = 21 771 683) and complete height, weight, sex and region data. The unadjusted prevalence rates of overweight/obesity were calculated by age, sex and region. In addition, the nationwide prevalence rates of overweight and obesity were standardized according to the 2010 China census by age group and sex. The prevalence of obesity-related complications by body mass index (BMI) groups was calculated using logistic regression.

Results

There were 15 770 094 eligible participants (median age 40 years; mean BMI 24.1 kg/m²; 52.8% male). By Chinese BMI classification, 34.8% were overweight and 14.1% were obese. Overweight and obesity were more prevalent in male than female participants (standardized: overweight 40.2% vs. 27.4%; obesity 17.6% vs. 9.6%, respectively). The prevalence of assessed complications was higher in participants with overweight/obesity versus those with normal BMI (P < 0.001 for trends). The most prevalent complications in participants with overweight/obesity were fatty liver disease, prediabetes, dyslipidaemia and hypertension. The number of complications increased with higher BMI.

Conclusions

Overweight/obesity and related complications are highly prevalent in this population. These data may better inform management and prevention public health strategies in China.

Abstract Image

查看原文本刊更多论文

中国肥胖及其相关并发症的患病率：1580万成年人的横断面真实世界研究

目的从中国一个大型的、横断面的、全国性的数据库中评估超重/肥胖及其相关并发症的患病率。材料与方法数据来自243个城市的519个美年健康体检中心。符合条件的参与者年龄≥18岁年，2019年进行常规检查（N = 21 771 683）以及完整的身高、体重、性别和区域数据。未经调整的超重/肥胖患病率按年龄、性别和地区计算。此外，根据2010年中国人口普查，按年龄组和性别对全国超重和肥胖的患病率进行了标准化。体重指数（BMI）组肥胖相关并发症的发生率采用逻辑回归计算。结果共有15个 770 094名符合条件的参与者（中位年龄40岁年；平均BMI 24.1 kg/m2；52.8%为男性）。根据中国的BMI分类，34.8%的人超重，14.1%的人肥胖。超重和肥胖在男性参与者中比女性参与者更普遍（标准化：超重分别为40.2%和27.4%；肥胖分别为17.6%和9.6%）。超重/肥胖参与者的评估并发症发生率高于BMI正常的参与者（P <；趋势为0.001）。超重/肥胖参与者最常见的并发症是脂肪肝、糖尿病前期、血脂异常和高血压。并发症的数量随着BMI的升高而增加。结论超重/肥胖及相关并发症在该人群中非常普遍。这些数据可以更好地为中国的公共卫生管理和预防策略提供信息。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes, Obesity & Metabolism 医学-内分泌学与代谢

CiteScore

10.90

自引率

6.90%

发文量

319

审稿时长

3-8 weeks

期刊介绍： Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.